



Drug Utilization Review Board Meeting Minutes July 9, 2024

DUR Board Members in attendance: Robert Wergin, M.D.
Virtual: Marin Broucek, M.D., Charlie Moore, R.P., Dave Randolph, R.P.

Nebraska Medicaid & LTC attendees in person: Dianne Garside, R.P., Leah Spencer, R.N.,
Program Specialist. Virtual: Spencer Moore, R.P.

Contracted attendees: Virtual: Kelly Flannagan, R.P., United Health Care; Jamie Benson,
R.P., Nebraska Total Care; Shannon Nelson, R.P., Molina Healthcare of Nebraska;
Shaleigh Hammons, Account executive, Magellan RX Management.

Public visitors in attendance in person: Amy Hornig, Abbvie; Randal Roth, Merck; Joe
Sullivan, Vertex. Others virtually.

I. Opening and Introductions

The meeting was called to order at 6:43 pm due to audio issues. The meeting was held
at the Best Western Plus Lincoln Inn & Suites in Lincoln, NE.

II. Conflict of Interest or changes

Robert Wergin disclosed that he is a candidate for presidency of NMA which is to be determined
in August, 2024.

III. Agenda approval

The agenda was unanimously approved.

IV. Approval of Minutes from DUR Board, May 7, 2024 meeting

Vote as follows: Marin Broucek-yes, Moore- yes, Randolph-yes, Wergin- abstain.

V. Special Topics

A. DUR Board Policy Review:

A revised draft of the DUR policy statement was presented to the Board with updated language
and clarification of Board member resignation, meeting frequency and manufacturer requirement
to provide prescribing information.

Vote as follows: Broucek-yes, Moore- yes, Randolph-yes, Wergin- no. The motion carried.

VI. Retrospective DUR

- A. Old Business-** none
- B. New Business:** none

VII. Prospective DUR

- A. Old Business-** none
- B. New Business-**none

1. Growth Hormone (GH) Annual Review

Dianne Garside reviewed the current prior authorization criteria and prior authorization (PA) form for GH. The draft changes are recommendations from the May P&T testimony. Robert Wergin discussed the psychosocial impact on children with familial short stature syndrome and the medical necessity of treatment. Criteria and PA drafted changes were unanimously approved.

VIII. Future Meeting Date

The next meeting is scheduled for Tuesday, September 10, 2024.

IX. Concerns & Comments

Board:

Some Board members questioned whether claims are being reimbursed at the increased professional dispensing fee designated for July 1, 2024. They will reach out to the respective MCOs for any discrepancies.

DUR Director and State representatives: It was noted that the Open Meetings Act is posted on the DHHS DUR website.

Magellan representatives: None

Managed Care Organization (MCO) representatives: None

Public attendees: None

X. Adjournment

The motion to adjourn the meeting was unanimously approved. The meeting was adjourned at 7:46 p.m.